Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.
about
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Targeting Anaplastic Lymphoma ...... ation ALK Inhibitor Ceritinib.
@en
Targeting Anaplastic Lymphoma Kinase
@nl
type
label
Targeting Anaplastic Lymphoma ...... ation ALK Inhibitor Ceritinib.
@en
Targeting Anaplastic Lymphoma Kinase
@nl
prefLabel
Targeting Anaplastic Lymphoma ...... ation ALK Inhibitor Ceritinib.
@en
Targeting Anaplastic Lymphoma Kinase
@nl
P2093
P2860
P50
P1433
P1476
Targeting Anaplastic Lymphoma ...... ration ALK Inhibitor Ceritinib
@en
P2093
Laurens van Houdt
Melissa H S Hillebrandt-Roeffen
Winette T A van der Graaf
P2860
P2888
P304
P356
10.1007/S11523-017-0528-Z
P577
2017-12-01T00:00:00Z